Bio-Techne Corporation (TECH) Stock Forecast
TECH analyst forecast
as of October 18, 2026- Analyst consensus
- Hold 3.15 / 5 from 13 analysts
- Price target
- $70.50 average of analyst targets
- Upside to target
- −2.9% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.40
- 52-week range
- $43.30 – $72.61
TECH analyst ratings
13 analystsNumber of analysts at each rating.
TECH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TECH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.45 | $0.42 | $0.49 | $0.42 | +6.9% | 7 |
| Next quarter (Dec '26) | $0.48 | $0.46 | $0.51 | $0.46 | +4.7% | 6 |
| Current fiscal year (FY2027) | $2.04 | $1.82 | $2.15 | $1.93 | +5.5% | 13 |
| Next fiscal year (FY2028) | $2.31 | $2.03 | $2.60 | $2.04 | +13.5% | 9 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TECH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $292.2M | $287.1M | $298.0M | +2.0% | 8 |
| Next quarter (Dec '26) | $307.8M | $303.7M | $313.3M | +4.0% | 7 |
| Current fiscal year (FY2027) | $1.27B | $1.25B | $1.29B | +4.3% | 12 |
| Next fiscal year (FY2028) | $1.40B | $1.35B | $1.50B | +10.0% | 9 |
TECH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TECH revenue: reported and forecast
TECH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.44 | $0.44 | $0.43 | $0.43 | $0.45 | +1.9% | 1 up · 0 down |
| Next quarter (Dec '26) | $0.48 | $0.48 | $0.47 | $0.47 | $0.48 | −0.2% | 1 up · 0 down |
| Current fiscal year (FY2027) | $2.05 | $2.05 | $2.02 | $2.02 | $2.04 | −0.4% | 2 up · 0 down |
| Next fiscal year (FY2028) | $2.30 | $2.30 | $2.31 | $2.31 | $2.31 | +0.5% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TECH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TECH beat in 10 of 12.
What analysts expect from TECH
13 analysts cover Bio-Techne; their consensus rating is hold (3.15 on a 1–5 scale, where 5 is a strong buy). The average price target is $70.50, 2.9% below the latest close of $72.57. Analysts expect earnings of $2.04 per share for FY2027, +5.5% from a year earlier. For FY2028 the average estimate is $2.31 per share on revenue of $1.4 billion. Bio-Techne beat the EPS estimate in 10 of the last 12 quarters.
Related: TECH income statement, TECH key metrics, TECH chart. See the TECH stock overview for the latest quote and news.
TECH forecast FAQ
What is Bio-Techne's price target?
The average analyst price target for Bio-Techne is $70.50, 2.9% below the latest close of $72.57.
Is Bio-Techne a buy, hold or sell?
Of 13 analysts covering Bio-Techne, 1 rate it a strong buy, 0 a buy, 12 a hold, 0 a sell and 0 a strong sell, a consensus of hold. Ratings are opinions, not a recommendation from Quotelinks.
What is Bio-Techne's EPS forecast?
Analysts forecast $2.04 per share for FY2027 (range $1.82 to $2.15); for FY2028 the estimate is $2.31.
What is Bio-Techne's revenue forecast?
The average revenue estimate for FY2027 is $1.3 billion, growth of 4.3%; for FY2028 it is $1.4 billion.
When does Bio-Techne report earnings?
Bio-Techne is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $0.40.
Does Bio-Techne usually beat earnings estimates?
Bio-Techne reported EPS at or above the analyst estimate in 10 of the last 12 quarters.